Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FSHD region gene 2 family member C (FRG2C) encodes a nuclear protein that is part of a family of chromatin-associated genes, some of which function as long noncoding RNAs involved in nuclear architecture and heterochromatin regulation[1][2]. FRG2C is predominantly expressed in fibroblasts, with tissue-specific regulation observed among FRG2 paralogs; its encoded protein is detected in the nucleus, and the gene locus is found on chromosome 3p12.3[1][2][3]. While FRG2 family members have been implicated in chromatin organization, only paralog FRG2A is functionally linked to muscular dystrophy (FSHD), through overexpression in muscle tissue of FSHD patients[2][5]. FRG2C itself is sometimes mutated in rare familial hyperphosphatemic tumoral calcinosis and spondyloarthropathy cases[3][4], but is not considered a therapeutic target, nor does it have established roles in major disease categories, drug interactions, or as a clinical biomarker. Its principal biological function appears to be related to heterochromatin regulation and the maintenance of nuclear architecture[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FSHD region gene 2 family member C (FRG2C).